Featured Stories
Interview: EULAR Head Counting The Cost Of Rheumatic Disease
Hans Bijlsma, president of the European League Against Rheumatism, tells Scrip about the progress being made in rheumatic and muskuloskeletal diseases, the areas where more innovation is needed and the importance of early treatment, both clinically and financially.
ViiV CEO: "We Aim To Be Top HIV Player By Mid-2020s"
ViiV CEO predicts strong pipeline and two-drug strategy will reinforces group's HIV market position and put it ahead of Gilead by the mid-2020s.
CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie
Pfizer's Ibrance has a strong lead in the CDK4/6 space, but Novartis' Kisqali and Lilly's Verzenio are looking to carve out their own niches, expand the category and move into earlier treatment settings. Another scramble is on as well, to answer the question: what comes next?
Latest News
Recent Tweets from ScripPharma Asset Insights
Innovation in the pharmaceutical industry has never been more exciting, and complicated. Disruptive technologies, such as artificial intelligence and digital health tools, and advanced therapeutic modalities including cell and gene therapies and antisense oligonucleotides demand that all health care stakeholders make efforts to move into the next generation of patient care and centricity.
Pharma Asset Insights provides a compilation of insights and data-driven analysis.
Shifting to a Unified Operating Model
The Veeva Unified Clinical Operations Survey of 300 clinical operations professionals from around the world examines the life sciences industry’s progress in reducing system and process complexity to improve study execution.
Survey results include:
- The most common clinical solutions challenges.
- Drivers and barriers to unifying clinical operations.
- The impact of CTMS Applications and eTMF on clinical operations.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Access To Widely Scattered Data A Major Challenge For Evolving Health Care Industry: EY Report
The Blockbusters No One Talks About
Drugs like Nexium, Lipitor, Lovenox and Plavix lost patent protection years ago, but continue to generate blockbuster level sales. Here's a look at the blockbuster brands that have stood the test of (generic) time.
Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes
Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.
Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
BI’s Business Development Focus Remains On Early Collaboration
Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.
Kala Hopes To Stride Into Dry Eye Market This Year
Kala Pharmaceuticals is hoping to shake up the dry eye market with a NDA filing this year for its steroid eye drop KPI-121 0.25%.
iTeos Says Adios To IDO And Eyes US IPO
An oversubscribed financing round led by new US investor MPM Capital has brought in $75m for the Belgian company. Much of it will be used to advance its potential best-in-class adenosine A2A receptor now that its IDO1 drug has been shelved.
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Ipsen CEO: 'I Assume a Hard Brexit', But Remain Bullish On UK Life Sciences
Ipsen's David Meek tells Scrip a Hard Brexit looks likely and that he's preparing the French pharma for that scenario.
Alexion Gets Speedy Review For Soliris Successor
Switching patients from the very expensive ultra rare disorder drug to ravulizumab will be a key strategy for Alexion if the latter is approved. Recent compelling data in paroxysmal nocturnal hemoglobinuria patients suggests the long-acting C5 complement inhibitor could offer more benefit than its predecessor with more convenient dosing.
Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction
Launch comes immediately after FDA approval of Dr. Reddy's and Mylan ANDAs while Indivior appeals district court ruling of non-infringement; Mylan settlement may delay its entry.
Big Pharma Voluntary List Price Reductions Doubtful, Sen. Warren Says
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Incyte Will File Jakafi For Acute GVHD In US Based On Phase II Success
The JAK1/2 inhibitor may add an indication for acute graft-versus-host disease, though based on a single, open-label Phase II trial that showed a 55% response rate in a high-mortality indication.
GC-Yuhan Orphan Alliance Signals Changing Korean Views On Open Innovation
In what appears to be the first open innovation-based partnership between leading South Korean pharma firms, GC Pharma and Yuhan have agreed to conduct joint early research on orphan drugs, capitalizing on each others' strengths. The move may herald a shift in domestic companies' views on such collaboration and a possible increase in similar tie-ups, amid their ongoing efforts to pursue innovation.
Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
Learning From Human Cell Hijacking Masters: ENYO Pharma Takes Virus Tricks Into Drug Discovery
Emerging Company Profile: ENYO Pharma has been around for barely four years, but it is already advancing its lead programs into Phase II trials in hepatitis B and NASH, and anticipates many more uses for its virology-based platform that will go way beyond treating virus infections.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.